What this band has actually done:
stocks scoring 25–45
beat the S&P 500 over the next three months
45.3%
of the time, across 39,662 cases
since 2015.
That is below a coin flip — and so is every other band, because the
median stock loses to a cap-weighted index.
How we measured this
Hedge funds
39
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$4.3B
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqCM
About VIKING THERAPEUTICS INC
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients…
Who's behind the signal
Every informed buyer we can see on VKTX, across all three feeds.
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar.
VIKING THERAPEUTICS INC isn't in the top-10 model right now, but 8 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
8
Investors
1
New positions
4
Increasing
3
Decreasing
0
Unchanged
Price History
Loading price data...
Return: High: Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
How much of each investor's portfolio is allocated to VIKING THERAPEUTICS INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell VIKING THERAPEUTICS INC or any security.
Get the Weekly Update
Every week, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.
Free forever · No spam · Unsubscribe anytime
ESC
Type to search across stocks, 50 investors & Congress.